Senators Question Why PBMs ‘Even Exist’ In Heated Hearing Amid Push For Reform

Senators pilloried the lack of transparency from pharmacy benefit managers during a hearing Thursday, as lawmakers hope to pass reforms this session.

The Senate Commerce Committee hosted the hearing amid concerns that PBMs steer patients toward pharmacies that they own. Lawmakers have introduced legislation to shed light on the issue, but some Republicans have balked over giving the federal government more authority.

“I don’t know why the hell they even exist,” said Sen. Jon Tester, D-Montana. “There is no transparency in PBMs. When you combine that with anti-competitive tactics, this is a recipe where the only people who win in healthcare costs are PBMs.”

For example, lawmakers noted that some PBMs will steer patients who need specialty drugs into their own mail-order pharmacies.

Pharmacies testified that contracts with PBMs include conditions that are unbearable and they have “zero negotiating power,” said Ryan Oftebro, CEO of the independent Kelley-Ross pharmacy group, at the hearing. Pharmacies have also complained about clawback fees where the PBM will recoup some of its payments to pharmacists for certain drugs.

Commerce Committee Chairwoman Sen. Maria Cantwell, D-Washington, decried the consolidation in the PBM market, where three companies have an 80% market share. She asked witnesses how the consolidation has impacted the drug supply chain.

Since many PBMs have their own specialty or regular pharmacies, there is “an entrenched set of incentives … to essentially steer funds to themselves, preferentially over the other independent pharmacies,” said Erin Trish, Ph.D., an economics professor at the University of Southern California.

The hearing is the latest example of bipartisan efforts to jump-start reforms in the industry. Last week, the Senate Judiciary Committee passed the Prescription Pricing for the People Act, which calls on the Federal Trade Commission (FTC) to study the industry and issue recommendations to Congress within one year.

Cantwell and Sen. Chuck Grassley, R-Iowa, co-sponsored that legislation and another bill called the PBM Transparency Act, which calls on the FTC to end clawback fees and spread pricing, another controversial practice where a PBM can upcharge a health plan for a drug’s cost and then pocket the difference.

Cantwell and Grassley pushed for PBM reform in the last Congress. While potential legislation did get out of committee, it never came up for a vote on the full Senate.

PBM industry group Pharmaceutical Care Management Association (PCMA) has pushed back on the legislative effort. The group released a new policy platform that lays out recommendations to address high drug prices.

The platform primarily lays the blame on drug companies for high prices, with recommendations to end anti-competitive practices such as “evergreening” and “patent thickets” that can stifle generic competition.

PCMA also argued that the PBM Transparency Act would constrain the ability of employers to lower drug costs.

“PCMA would welcome the opportunity to work with the committee to advance policies that will address prescription drug affordability without undermining the parts of the system that have been proven to drive value for patients and employers,” said PCMA President and CEO J.C. Scott in a statement before the hearing.

Even though PBM reforms have some bipartisan support, other Republicans on the Commerce Committee instead focused on controversies at the FTC, where the lone Republican commission member resigned in protest.

Ranking Member Ted Cruz, R-Texas, questioned whether PBMs deserve the scrutiny they are receiving, as well as the need to give the FTC “substantial regulatory power,” as he claims the bills would do. Cruz added the bill would prejudge an ongoing FTC probe on the PBM industry.

“I’ve long had concerns with the FTC’s vague statutory authority,” he said.

Grassley pushed back during the hearing, saying that the bipartisan legislation doesn’t give the FTC “any new power or regulatory authority.”

 

Source Link

Recommended Articles

HHS Proposes New Cybersecurity Requirements As First Major HIPAA Update In 10 Years

The Department of Health and Human Services (HHS) proposed a rule days before the new year began that would hold healthcare organizations to a higher standard for protecting sensitive healthcare information from security threats like cyberattacks. The proposal would require that entities covered by the Health Information Portability and Accountability Act (HIPAA) achieve specific technical ...

Read More

Aetna Sues Drugmakers For Widespread Price-Fixing And Collusion

Aetna is taking legal action against Pfizer, Novartis, Teva Pharmaceuticals and others, saying the list of drugmakers conspired to overcharge the insurer, consumers and the federal government for generic drugs. The complaint (PDF), filed Dec. 31, claims the drugmakers communicated secretly at trade conferences or through phone calls, beginning in 2012, to determine the market share, prices ...

Read More

Biden Administration Bars Medical Debt From Credit Scores

The federal Consumer Financial Protection Bureau on Tuesday issued new regulations barring medical debts from American credit reports, enacting a major new consumer protection just days before President Joe Biden is set to leave office. The rules ban credit agencies from including medical debts on consumers’ credit reports and prohibit lenders from considering medical information ...

Read More

Two Employer Health Coverage Reporting Bills Become Law

President Joe Biden has signed two bills that will ease some Affordable Care Act health coverage reporting requirements for employers. One is the Paperwork Burden Reduction Act, and the other is the Employer Reporting Improvement Act bill. The new laws affect the Form 1095-B and Form 1095-C notices that employers use to tell employees and the Internal Revenue Service about ...

Read More
arrowcaret-downclosefacebook-squarehamburgerinstagram-squarelinkedin-squarepauseplaytwitter-squareyoutube-square